Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comparison of S. boulardii cells in H2O vs. S. boulardii cells in H2O+HCl

ABSTRACT: We sought to better understand the mechanism of acid-induced cell death in Saccharomyces boulardii--a probiotic yeast routinely used to prevent and treat gastrointestinal disorders. To do this we generated microarray gene expression profiles of S. boulardii cells cultured in an acidic environment.

ORGANISM(S): Saccharomyces boulardii (nom. inval.)

PROVIDER: GSE43271 | GEO | 2013/01/04

SECONDARY ACCESSION(S): PRJNA185195

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Comparison of S. boulardii cells in H2O vs. S. boulardii cells in H2O+HCl

Project description:We sought to better understand the mechanism of acid-induced cell death in Saccharomyces boulardii--a probiotic yeast routinely used to prevent and treat gastrointestinal disorders. To do this we generated microarray gene expression profiles of S. boulardii cells cultured in an acidic environment. Two samples were analyzed. One replicate per array.

2013-01-04 | E-GEOD-43271 | biostudies-arrayexpress

RNA-seq analysis of Lactobacillus at acidic stress

Project description:To understand transcriptional regulation of probiotic bacteria under acidic condition, RNAseq analysis was carried out over different growth conditions

2017-11-29 | GSE107337 | GEO

Comparative genomic hybridization of Saccharomyces boulardii and Saccharomyces cerevisiae to determine genomic differences

Project description:A comparative genomic hybridisation experiment using Affymetrix YG-S98 arrays to study the genetic background of S. Boulardii compared to S. Cerevisiae strain BY4743. Background: Saccharomyces boulardii, a yeast that was isolated from fruit in Indochina has been used as a remedy for diarrhoea since 1950, and is now a commercially available treatment throughout Europe, Africa and South America. Though initially classified as a separate species of Saccharomyces, recent publications have shown that the genome of S. boulardii is so similar to Saccharomyces cerevisiae that the two should be classified as conspecific. This raises the question of the distinguishing molecular and phenotypic characteristics present in S. boulardii that make it perform more effectively as a probiotic organism compared to other strains of S. cerevisiae. This investigation reports some of these characteristics including enhanced ability for pseudohyphal switching upon nitrogen limitation and increased resistance to acidic pH. However, these differences did not correlate with increased adherence to epithelial cells or transit through mouse gut. Pertinent characteristics of the S. boulardii genome such as trisomy of chromosome IX, altered copy number of a number of individual genes and sporulation deficiency have been revealed by comparative genome hybridisation using oligonucleotide-based microarrays coupled with a rigorous statistical analysis. The contributions of the different genomic and phenotypic features of S. boulardii to its probiotic nature are discussed.

2006-11-10 | E-MAXD-15 | biostudies-arrayexpress

Probiotic Therapy in Preventing Gastrointestinal Complications in Patients Undergoing Chemotherapy and Pelvic Radiation Therapy

Project description:RATIONALE: Probiotic therapy may reduce or prevent gastrointestinal complications in patients undergoing chemotherapy and pelvic radiation therapy. PURPOSE: This randomized phase III trial is studying how well probiotic therapy works in preventing gastrointestinal complications in patients undergoing chemotherapy and pelvic radiation therapy.

| 2115790 | ecrin-mdr-crc

K5 capsule and lipopolysaccharide are important in resistance to T4 phage attack in probiotic E. coli strain Nissle 1917

Project description:Rapidly growing antibiotic resistance among gastrointestinal pathogens, and the ability of antibiotics to induce the virulence of these pathogens makes it increasingly difficult to rely on antibiotics to treat gastrointestinal infections. The probiotic E. coli strain Nissle 1917 (EcN) is the active component of the pharmaceutical preparation Mutaflor® and has been successfully used in the treatment of gastrointestinal disorders. Gut bacteriophages are dominant players in maintaining the microbial homeostasis in the gut, however, their interaction with incoming probiotic bacteria remains to be at conception. The presence of bacteriophages in the gut makes it inevitable for any probiotic bacteria to be phage resistant, in order to survive and successfully colonize the gut. This study addresses the phage resistance of EcN, specifically against lytic T4 phage infection. From various experiments we could show that i) EcN is resistant towards T4 phage infection, ii) EcN’s K5 polysaccharide capsule plays a crucial role in T4 phage resistance and iii) EcN’s lipopolysaccharide (LPS) inactivates T4 phages and notably, treatment with the antibiotic polymyxin B which neutralizes the LPS destroyed the phage inactivation ability of isolated LPS from EcN. Our results further indicate that N-acetylglucosamine at the distal end of O6 antigen in EcN’s LPS could be the interacting partner with T4 phages. From our findings, we have reported for the first time, the role of EcN’s K5 capsule and LPS in its defense against T4 phages. In addition, by inactivating the T4 phages, EcN also protects E. coli K-12 strains from phage infection in tri-culture experiments. The combination of the identified properties is not found in other tested commensal E. coli strains. Furthermore, our research highlights phage resistance as an additional safety feature of EcN, a clinically successful probiotic E. coli strain.

2019-08-27 | GSE135946 | GEO

Expression data from Caenorhabditis elegans fed with the bacterial strain Bifidobacterium animalis sbsp. lactis CECT 8145

Project description:Modulation of gut microbiota through probiotic supplementation is an interesting strategy to prevent obesity We use microarrays to study the global genome expression of C. elegans fed with the probiotic strain Bifidobacterium animalis sbsp. lactis CECT 8145

2015-11-22 | GSE63531 | GEO

Differential Targeting of the E-Cadherin and b-Catenin Complex by Gram-positive Probiotic Lactobacilli Improves Epithelial Barrier Function

Project description:The intestinal ecosystem is balanced by dynamic interactions between resident and incoming microbes, the gastrointestinal barrier, and the mucosal immune system. However, in the context of inflammatory bowel diseases (IBD) where the integrity of the gastrointestinal barrier is compromised, resident microbes contribute to the development and perpetuation of inflammation and disease. In this context, probiotic bacteria exert beneficial effects enhancing epithelial barrier integrity. However, the mechanisms underlying these beneficial effects are only poorly understood. Here, we comparatively investigated the effects of four probiotic lactobacilli, namely L. acidophilus, L. fermentum, L. gasseri, and L. rhamnosus in a T84 cell epithelial barrier model. Results of DNA-microarray experiments indicating that lactobacilli modulate the regulation of genes encoding in particular adherence junction proteins such as E-cadherin and b-catenin were confirmed by qRT-PCR. Furthermore, we show that epithelial barrier function is modulated by Gram-positive probiotic lactobacilli via their effect on adherence junction protein expression and complex formation. In addition, incubation with lactobacilli differentially influences the phosphorylation of adherence junction proteins and of PKC isoforms such as PKCd which thereby positively modulates epithelial barrier function. Further insight into the underlying molecular mechanisms triggered by these probiotics might also foster the development of novel strategies for the treatment of gastrointestinal diseases (e.g. IBD).

2012-02-10 | E-MEXP-3445 | biostudies-arrayexpress

Impact of Probiotics on the Intestinal Microbiota

Project description:The purpose of this study is to assess the impact of probiotic administration (Saccharomyces boulardii) on patients undergoing colorectal resections comparing to the routine protocol by assessing: (1)intestinal microbiota modulation using RT-PCR to measure cytokine in the mucosa; (2) assess postoperative complications, mainly infectious and mortality, as well as length of hospital stay

| 2126204 | ecrin-mdr-crc

Characteristic of extracellular vesicles of probiotic yeasts Saccharomyces boulardii

Project description:Identifictaion of proteins from extracellular vesicles of probiotic yeasts Saccharomyces boulardii. This work was financially supported by the National Science Centre, Poland (grant number 2021/43/D/NZ6/01464).

2023-05-24 | PXD039137 | Pride

Proteomic analysis of outer membrane vesicles from the probiotic strain Escherichia coli Nissle 1917

Project description:Escherichia coli Nissle 1917 (EcN) is a probiotic used for treatment of intestinal disorders. EcN improves gastrointestinal homeostasis and microbiota balance; however little is known about how this probiotic delivers effector molecules to the host. Outer membrane vesicles (OMVs) are constitutively produced by gram-negative bacteria and have a relevant role in bacteria-host interactions. Here we performed proteomic analysis of EcN OMVs. Using 1D SDSD-PAGE and highly sensitive LC-MS/MS analysis we identified 192 EcN vesicular proteins with high confidence in three independent experiments. Of these proteins, 18 were encoded by strain-linked genes and 57 were common to pathogen-derived OMVs. These proteins may contribute to the ability of this probiotic to colonize the human gut as they fulfil functions related to adhesion to host tissues, immune modulation or bacterial survival in host niches. This study describes the first global OMV proteome of a probiotic strain and provides evidence that probiotic-derived OMVs contain proteins that can target these vesicles to the host and mediate their beneficial effects on intestinal function.

2013-12-19 | PXD000367 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data